Evaluating the ADNEX model for diagnosing ovarian tumors in Dutch hospitals
Official title: Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice
Run by Maxima Medical Center · NCT06103916 · Data updated 2026-11-12
This study is testing if the ADNEX model can help doctors in the Netherlands tell the difference between benign and malignant ovarian tumors in patients with complex ovarian issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 613 (estimated) |
| Sponsor | Maxima Medical Center Academic / other |
| Locations | 1 site (Veldhoven, North Brabant) |
| Status | Recruiting |
| Started | July 15, 2022 |
| Main results expected | August 2027 |
| Study ends | May 2028 |
| Registry record updated | October 27, 2023 |
| Trial ID | NCT06103916 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 18 and older with complex ovarian tumors who can understand Dutch.
✕Probably not a fit
Patients with benign ovarian tumors that meet specific IOTA criteria or those with a prior histologically proven malignancy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter prospective cohort study aims to assess the diagnostic accuracy of the IOTA ADNEX model in distinguishing between benign and malignant ovarian tumors in Dutch gynecological practice. Patients aged 18 and older with complex ovarian tumors who have undergone ultrasound assessments according to IOTA criteria will have their data recorded in a database. The study seeks to provide clinical data on the performance of the ADNEX model, which has shown promise in previous validation studies but needs evaluation in everyday clinical settings. The findings will help inform treatment decisions and referral practices in the Netherlands.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of ovarian tumor diagnoses, leading to better treatment outcomes for patients.
How similar studies have gone: Previous studies have shown the ADNEX model to have superior diagnostic accuracy compared to older risk-assessment strategies, but this study will evaluate its effectiveness in routine clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Presence of a complex ovarian tumor 3. Ultrasound assessment in accordance with IOTA definitions and application of the ADNEX model 4. Understanding of Dutch language Exclusion Criteria: 1. Women with an ovarian tumor that meets the IOTA criteria of a benign easy descriptor: 1. Unilocular tumor with ground glass echogenicity in premenopausal woman suggestive of endometrioma 2. Unilocular tumor with mixed echogenicity and acoustic shadows in premenopausal women (suggestive of benign cystic teratoma) 3. Unilocular tumor with regular walls and maximal diameter \< 10cm (suggestive of simple cyst or cystadenoma) 4. Remaining unilocular tumors with regular walls 2. Histologically proven malignancy prior to ultrasound
Where it's running
-
Máxima Medical Centre
Veldhoven, North Brabant, Netherlands Recruiting
Study contacts
- Study coordinator: Esther Lems, MD
- Email: PRIORITY@mmc.nl
- Phone: +31 40 888 83 80
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.